Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (541-550 of 745) with videos related to

Pageof 75
Sort By:
Nature Communications|July 21, 2024
The genetic evolution of acral melanomaMeng Wang, Satoshi Fukushima, Yi-Shuan Sheen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2014
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumorsJordi Rodon, Hussein A Tawbi, Anne L Thomas, et al.
The Lancet. Oncology|February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trialReinhard Dummer, Jan C Brase, James Garrett, et al.
Nature Communications|January 23, 2015
The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressorsDaniel Zingg, Julien Debbache, Simon M Schaefer, et al.
The Lancet. Oncology|May 19, 2015
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialNicole Basset-Seguin, Axel Hauschild, Jean-Jacques Grob, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2017
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017Franz Trautinger, Johanna Eder, Chalid Assaf, et al.
Plos Genetics|January 29, 2015
Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanomaOlga Shakhova, Phil Cheng, Pravin J Mishra, et al.
The Lancet. Oncology|June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind studyGeorgina V Long, Reinhard Dummer, Omid Hamid, et al.
The New England Journal of Medicine|September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaReinhard Dummer, Axel Hauschild, Mario Santinami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2022
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With <i>BRAF</i> V600-Mutant MelanomaReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Pageof 75

Showing results (541-550 of 745) with videos related to

Sort By:
Pageof 75
Nature Communications|July 21, 2024
The genetic evolution of acral melanomaMeng Wang, Satoshi Fukushima, Yi-Shuan Sheen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2014
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumorsJordi Rodon, Hussein A Tawbi, Anne L Thomas, et al.
The Lancet. Oncology|February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trialReinhard Dummer, Jan C Brase, James Garrett, et al.
Nature Communications|January 23, 2015
The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressorsDaniel Zingg, Julien Debbache, Simon M Schaefer, et al.
The Lancet. Oncology|May 19, 2015
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialNicole Basset-Seguin, Axel Hauschild, Jean-Jacques Grob, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2017
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017Franz Trautinger, Johanna Eder, Chalid Assaf, et al.
Plos Genetics|January 29, 2015
Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanomaOlga Shakhova, Phil Cheng, Pravin J Mishra, et al.
The Lancet. Oncology|June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind studyGeorgina V Long, Reinhard Dummer, Omid Hamid, et al.
The New England Journal of Medicine|September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaReinhard Dummer, Axel Hauschild, Mario Santinami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2022
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With <i>BRAF</i> V600-Mutant MelanomaReinhard Dummer, Keith T Flaherty, Caroline Robert, et al.
Pageof 75